SV

Street Verdict

Analyst Scorecard

A record of what Motilal Oswal Analysis said publicly, with the source. Not advice.

“Initiated coverage on Biocon with a 'Buy' rating and a target price of Rs 410, implying a 13% upside from the current market price of Rs 360. The company is expanding peptide API capacity for Semaglutide ahead of its patent expiry in March 2026, aiming to capture projected demand. Biocon is strategically pursuing CDMO and front-end models with lower manufacturing costs. Motilal Oswal projects sales CAGR of 18% in Biologics, 16% in Generics, and 10% in Syngene over FY25–27.”

Motilal Oswal Analysis’s track record (trackable calls only): 453 graded calls · 95% CI 36–45%

BioconBullishCalled 17 Sep 2025Graded 13 Nov 2025
Verdict:HIT

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹410, as stated.

Window: 12 months, the default when no time frame is stated.

The target ₹410 was reached on a close. Hit.

The grader’s working: R4 TARGET_CALL: entered ₹368.4 on 2025-09-18 (next trading session's close); target ₹410 reached at close ₹417 on 2025-11-13. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

How it played out

How this is worked out
Time to target
The target was reached on a close 37 trading sessions (56 calendar days) after the entry.
Worst close against it
The closing price went as far as 8.01% against the call before the target was reached, measured from the entry price. Closing prices only; an intraday dip is never counted.

From the entry the grade used, on closing prices. This is a record of one past call and is not advice.

Tracking Biocon since this call

1-year tracking window
Read the original articleSee Motilal Oswal Analysis’s full track record